Insider Selling: Caribou Biosciences, Inc. (NASDAQ:CRBU) Insider Sells $35,506.37 in Stock

Caribou Biosciences, Inc. (NASDAQ:CRBUGet Rating) insider Syed Ali-Aamir Rizvi sold 5,627 shares of the business’s stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $6.31, for a total transaction of $35,506.37. Following the sale, the insider now owns 59,373 shares of the company’s stock, valued at approximately $374,643.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Caribou Biosciences Stock Performance

Shares of CRBU opened at $6.39 on Monday. Caribou Biosciences, Inc. has a 1 year low of $4.89 and a 1 year high of $13.19. The company has a market cap of $389.80 million, a price-to-earnings ratio of -4.23 and a beta of 1.85. The firm has a fifty day moving average of $7.76 and a 200-day moving average of $8.93.

Caribou Biosciences (NASDAQ:CRBUGet Rating) last announced its quarterly earnings results on Tuesday, November 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.04. Caribou Biosciences had a negative net margin of 714.82% and a negative return on equity of 26.66%. The company had revenue of $3.30 million during the quarter, compared to the consensus estimate of $3.63 million. Analysts predict that Caribou Biosciences, Inc. will post -1.73 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Citigroup lowered their target price on shares of Caribou Biosciences from $38.00 to $37.00 in a research note on Wednesday, November 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $27.80.

Hedge Funds Weigh In On Caribou Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of CRBU. Swiss National Bank boosted its holdings in shares of Caribou Biosciences by 8.0% during the first quarter. Swiss National Bank now owns 57,000 shares of the company’s stock valued at $523,000 after acquiring an additional 4,200 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Caribou Biosciences by 22.1% during the first quarter. ProShare Advisors LLC now owns 15,766 shares of the company’s stock valued at $145,000 after acquiring an additional 2,856 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Caribou Biosciences by 2,754.9% during the first quarter. JPMorgan Chase & Co. now owns 515,758 shares of the company’s stock valued at $4,735,000 after acquiring an additional 497,692 shares during the period. Bank of New York Mellon Corp lifted its holdings in Caribou Biosciences by 108.2% in the first quarter. Bank of New York Mellon Corp now owns 141,262 shares of the company’s stock worth $1,297,000 after purchasing an additional 73,427 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in Caribou Biosciences by 311.7% in the first quarter. MetLife Investment Management LLC now owns 31,003 shares of the company’s stock worth $285,000 after purchasing an additional 23,472 shares during the period. Institutional investors and hedge funds own 70.44% of the company’s stock.

About Caribou Biosciences

(Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.

Featured Articles

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.